Hemab Therapeutics advances its clinical pipeline with the start of a pivotal Phase 3 trial for sutacimig and reports positive early-stage data for its Factor VII deficiency and heavy menstrual bleeding programs.
The Q3 2026 report is dominated by pipeline progress: initiation of the SOLARA pivotal Phase 3 trial of sutacimig in Glanzmann thrombasthenia in November, first positive Phase 2b clinical data in Factor VII deficiency (prothrombin time shortened by more than 50%, ~5x FVII(a) accumulation), and first patient dosed in the Phase 1 HMB-003 trial. These advance the portfolio toward Phase 3 and expand addressable markets, a positive for a clinical-stage biotech. However, no financial figures or guidance changes appear in the report, and the FDA recommended a randomized design for SOLARA that the com
Hemab Therapeutics reported Q3 2026 results, highlighting the initiation of the pivotal Phase 3 SOLARA trial for sutacimig in Glanzmann thrombasthenia. The company also reported positive Phase 2b clinical data for sutacimig in Factor VII deficiency and dosed the first participant in its Phase 1 trial for HMB-003. Hemab maintains a strong cash position of $430.2 million, providing an operational runway into 2029.
The company started its first pivotal Phase 3 trial (SOLARA) in Glanzmann thrombasthenia, dosed the first participant in a Phase 1 trial for heavy menstrual bleeding, and showed early clinical activity for sutacimig in Factor VII deficiency, moving its pipeline closer to market.
The FDA had recommended a randomized controlled design for the SOLARA trial, but Hemab is running it as a single-arm study, which could pose a regulatory hurdle. Early FVIID results also come from only two participants.